Distinguishing Characteristics between Pandemic 2009–2010 Influenza A (H1N1) and Other Viruses in Patients Hospitalized with Respiratory Illness

Philip A. Chan¹,², Leonard A. Mermel¹,², Sarah B. Andrea³, Russell McCulloh¹,⁵, John P. Mills², Ignacio Echenique², Emily Leveen², Natasha Rybak², Cheston Cunha², Jason T. Machan⁶, Terrance T. Healey⁷, Kimberle C. Chapin²,³,*

¹ Division of Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island, United States of America, ² Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America, ³ Department of Pathology, Rhode Island Hospital, Providence, Rhode Island, United States of America, ⁴ Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island, United States of America, ⁵ Department of Pediatrics, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America, ⁶ Department of Orthopedics and Surgery, Rhode Island Hospital, Providence, Rhode Island, United States of America, ⁷ Department of Radiology, Rhode Island Hospital, Providence, Rhode Island, United States of America

Abstract

Background: Differences in clinical presentation and outcomes among patients infected with pandemic 2009 influenza A H1N1 (pH1N1) compared to other respiratory viruses have not been fully elucidated.

Methodology/Principal Findings: A retrospective study was performed of all hospitalized patients at the peak of the pH1N1 season in whom a single respiratory virus was detected by a molecular assay targeting 18 viruses/subtypes (RVP, Luminex xTAG). Fifty-two percent (615/1192) of patients from October, 2009 to December, 2009 had a single respiratory virus (291 pH1N1; 207 rhinovirus; 45 RSV A/B; 37 parainfluenza; 27 adenovirus; 6 coronavirus; and 2 metapneumovirus). No seasonal influenza A or B was detected. Individuals with pH1N1, compared to other viruses, were more likely to present with fever (92% & 70%), cough (92% & 86%), sore throat (32% & 16%), nausea (31% & 8%), vomiting (39% & 30%), abdominal pain (14% & 7%), and a lower white blood count (8,500/L & 13,600/L, all p-values<0.05). In patients with cough and gastrointestinal complaints, the presence of subjective fever/chills independently raised the likelihood of pH1N1 (OR 10). Fifty-five percent (336/615) of our cohort received antibacterial agents, 63% (385/615) received oseltamivir, and 41% (252/615) received steroids. The mortality rate of our cohort was 1% (7/615) and was higher in individuals with pH1N1 compared to other viruses (2.1% & 0.3%, respectively; p = 0.04).

Conclusions/Significance: During the peak pandemic 2009–2010 influenza season in Rhode Island, nearly half of patients admitted with influenza-like symptoms had respiratory viruses other than influenza A. A high proportion of patients were treated with antibiotics and pH1N1 infection had higher mortality compared to other respiratory viruses.

Introduction

Viral respiratory illnesses are responsible for large numbers of hospital admissions each year leading to substantial morbidity and mortality [1]. The etiologic agents include a diverse group of viruses, such as influenza A which is responsible for intermittent pandemics [2]. Reassortment of swine-origin and human strains led to circulating pH1N1 [3,4] and a significant increase in hospital admissions during the 2009–2010 influenza season.

Timely identification of influenza is important as the administration of neuraminidase inhibitors may limit duration and severity of illness if given early [5]. Rapid tests were found to be insensitive in the diagnosis of pH1N1 [6] and unable to subtype the influenza virus. Molecular techniques replaced some of these tests, but the availability, expense and technical training limited widespread use of this technology [7]. Therefore, many clinicians relied on clinical symptoms to diagnose influenza during the pandemic [8].

The classic influenza-like illness (ILI), defined as fever and cough and/or sore throat, is often used to distinguish influenza from other respiratory viruses. However, other viruses such as respiratory syncytial virus (RSV A/B), rhinovirus, parainfluenza, adenovirus, metapneumovirus, and coronavirus, can cause a similar illness and circulate at the same time as influenza [1,9]. Using ILI symptoms to diagnose influenza is neither sensitive nor specific [10,11]. Other symptoms reported during the pandemic included gastrointestinal complaints [12–19], leukopenia [14,20,21], elevated aminotransferase levels [14], thrombocytopenia and other laboratory abnormalities [14,20–24]. Although the
clinical characteristics of pH1N1 infection may be similar to seasonal influenza [25,26], there is scant data in the literature comparing pH1N1 with other respiratory viruses.

The inability to reliably diagnose a viral respiratory infection such as influenza A, often leads to coverage of possible bacterial etiologies [27]. Overage of antibiotics is not without consequence and can lead to complications including Clostridium difficile infection and high rates of resistance [28]. Thus, an accurate diagnosis of influenza and other respiratory viral infections is important to avoid overuse of antibacterial agents and direct appropriate antiviral therapy.

In response to the diagnostic challenges presented by influenza infection, our hospital system instituted a polymerase chain reaction (PCR)-based molecular panel that was able to identify 18 different respiratory viruses. The aim of this study was to examine differences in clinical, laboratory and radiographic findings between pH1N1 and other respiratory viruses with the goal to assist clinicians in more effectively diagnosing and treating pH1N1. To our knowledge, this is the first study to directly compare clinical parameters of pH1N1 to other respiratory viruses using a sensitive molecular diagnostic methodology in a large cohort.

Results

During our peak pH1N1 season, 1,438 RVP samples were collected. Of these, 1192 were from inpatients (340 samples in patients <5 years, 240 samples 5–18 years, and 612 samples ≥19 years). Six-hundred and fifteen patients with positive results were included in the final analysis (Figure 1) with a mean age of 20 years (range: 0–97 years). Forty-seven percent of patients had pH1N1 and 53% had another respiratory virus with rhinovirus being the second most prevalent in the population analyzed (34%, Table 1). Fewer patients with pH1N1 were under the age of five years compared to those with other viruses and individuals with pH1N1 were less likely to have cardiac co-morbidities, malignancy, or be admitted from a nursing home. Individuals with pH1N1 were more likely to report a sick contact or to use tobacco.

Individuals with pH1N1 were more likely to present with the following symptoms when compared to those with other respiratory viruses: subjective fever or chills, sore throat, nausea, vomiting, abdominal pain, weakness, fatigue, myalgias, and chest pain. Patients with other respiratory viruses were more likely to present with changes in mental status including dizziness or lethargy (Table 2).

On presentation to the emergency room, patients with pH1N1 exhibited a higher maximum temperature, lower maximum heart rate, respiratory rate, systolic blood pressure, and oxygen saturation (Table 3). Patients with pH1N1 were more likely to have lower white blood counts, platelet counts, and potassium levels. Alternatively, patients with pH1N1 were more likely to have higher hemoglobin/hematocrit and albumin levels.

Of the 529 patients who received a chest radiograph, a greater number of patients with pH1N1 had no acute findings compared to other respiratory viruses (Table 4). Other respiratory viruses were more likely to have an interstitial opacity consistent with viral infection on chest radiograph. Thirty percent (161/529) of patients with a chest radiograph had focal or multi-focal airspace findings. Most patients with pH1N1 (79.0%) received oseltamivir. More than half received antibacterial agents, and one-third received steroids (Table 5). Of the total cohort, only 9.6% had a sputum sample of which 27% were positive for a potential pathogenic
**Table 1.** Characteristics and demographics of patients presenting with pandemic influenza A (pH1N1) compared to other respiratory viruses.

| Age (years) | Total (n = 615) | Influenza A, H1N1 (n = 291) | All Others (n = 324) | Rhinovirus (n = 207) | RSV (n = 45) | Adenovirus (n = 27) | Parainfluenza (n = 37) | Coronavirus (n = 6) | Metapneumovirus (n = 2) | p-value OR* |
|-------------|-----------------|-----------------------------|----------------------|----------------------|--------------|---------------------|-----------------------|---------------------|------------------------|-------------|
| 5< to 18    | 23.6% (145)     | 32.3% (94)                  | 16.7% (51)           | 16.4% (34)           | 6.7% (3)     | 22.2% (6)           | 21.6% (8)             | 0% (0)              | 0% (0)                 | 10.1 [0.52–1.95]  |
| 19 to 59    | 29.4% (181)     | 41.2% (120)                 | 18.8% (61)           | 22.2% (46)           | 2.2% (1)     | 29.6% (8)           | 10.8% (4)             | 0% (0)              | 16.7% (1)              | 5.43 [3.55–8.29]  |
| ≥60         | 9.1% (56)       | 5.2% (15)                   | 12.7% (41)           | 13.5% (28)           | 6.7% (3)     | 3.7% (1)            | 18.9% (7)             | 33.3% (2)           | 0% (0)                 | 5.08 [3.25–7.96]  |

**Gender**

|              | Total (n = 615) | Influenza A, H1N1 (n = 291) | All Others (n = 324) | Rhinovirus (n = 207) | RSV (n = 45) | Adenovirus (n = 27) | Parainfluenza (n = 37) | Coronavirus (n = 6) | Metapneumovirus (n = 2) | p-value OR* |
|--------------|-----------------|-----------------------------|----------------------|----------------------|--------------|---------------------|-----------------------|---------------------|------------------------|-------------|
| Male         | 53.5% (329)     | 52.9% (154)                 | 54.0% (175)          | 52.2% (108)          | 48.3% (100)  | 46.7% (136)         | 42.9% (139)           | 48.3% (100)         | 46.7% (136)            | 42.9% (139)  |
| Female       | 46.5% (286)     | 47.1% (137)                 | 46.0% (149)          | 47.8% (99)           | 31.1% (14)   | 37.0% (10)          | 32.4% (12)            | 37.0% (10)         | 37.0% (10)             | 32.4% (12)  |

**Co-morbidities**

|              | Total (n = 615) | Influenza A, H1N1 (n = 291) | All Others (n = 324) | Rhinovirus (n = 207) | RSV (n = 45) | Adenovirus (n = 27) | Parainfluenza (n = 37) | Coronavirus (n = 6) | Metapneumovirus (n = 2) | p-value OR* |
|--------------|-----------------|-----------------------------|----------------------|----------------------|--------------|---------------------|-----------------------|---------------------|------------------------|-------------|
| Respiratory* | 44.7% (275)     | 46.7% (136)                 | 42.9% (139)          | 48.3% (100)          | 35.6% (16)   | 37.0% (10)          | 32.4% (12)            | 32.4% (12)         | 32.4% (12)             | 0.34        |
| Asthma/COPD  | 37.4% (230)     | 39.9% (115)                 | 35.5% (115)          | 42.0% (87)           | 22.2% (10)   | 37.0% (10)          | 21.6% (8)             | 0% (0)              | 0% (0)                 | 0.30        |
| Hepatic*     | 2.9% (18)       | 4.1% (12)                   | 1.9% (6)             | 2.9% (6)             | 0% (0)       | 0% (0)              | 0% (0)                | 0% (0)              | 0% (0)                 | 0.10        |
| Renal*       | 2.4% (15)       | 2.4% (7)                    | 2.5% (8)             | 2.4% (5)             | 0% (0)       | 0% (0)              | 0% (0)                | 0% (0)              | 0% (0)                 | 0.96        |
| Malignancy   | 6.0% (37)       | 7.7% (8)                    | 9.0% (29)            | 9.2% (19)            | 4.4% (2)     | 7.4% (2)            | 10.8% (4)             | 33.3% (2)           | 33.3% (2)              | <0.01       |
| Neurological* | 11.2% (69)      | 12.7% (37)                  | 9.9% (32)            | 8.7% (18)            | 11.1% (5)    | 0% (0)              | 18.9% (7)             | 33.3% (2)           | 33.3% (2)              | 0.27        |
| Cardiac      | 12.5% (77)      | 9.6% (28)                   | 15.1% (49)           | 16.4% (34)           | 8.9% (4)     | 7.4% (2)            | 18.9% (7)             | 16.7% (1)           | 50.0% (1)              | 0.04        |
| HIV*         | 1.8% (11)       | 1.4% (4)                    | 2.2% (7)             | 3.4% (7)             | 0% (0)       | 0% (0)              | 0% (0)                | 0% (0)              | 0% (0)                 | 0.46        |
| Immuno-compromised* | 6.2% (38) | 4.8% (14) | 7.4% (24) | 9.2% (19) | 2.2% (1) | 0% (0) | 5.4% (2) | 16.7% (1) | 50.0% (1) | 0.18 |

**Other**

|              | Total (n = 615) | Influenza A, H1N1 (n = 291) | All Others (n = 324) | Rhinovirus (n = 207) | RSV (n = 45) | Adenovirus (n = 27) | Parainfluenza (n = 37) | Coronavirus (n = 6) | Metapneumovirus (n = 2) | p-value OR* |
|--------------|-----------------|-----------------------------|----------------------|----------------------|--------------|---------------------|-----------------------|---------------------|------------------------|-------------|
| Tobacco      | 15.6% (96)      | 21.0% (61)                  | 10.8% (35)           | 11.1% (33)           | 2.2% (1)     | 25.9% (7)           | 10.8% (4)             | 0% (0)              | 0% (0)                 | <0.01       |
| Nursing Home | 2.1% (13)       | 0.7% (2)                    | 3.4% (11)            | 5.3% (11)            | 0% (0)       | 0% (0)              | 0% (0)                | 0% (0)              | 0% (0)                 | 0.02        |
| Sick Contacts| 34.0% (209)     | 43.0% (125)                 | 25.9% (84)           | 24.2% (50)           | 28.9% (13)   | 25.9% (7)           | 29.7% (11)            | 33.3% (2)           | 33.3% (2)              | <0.01       |
| Pregnant     | 1.3% (8)        | 1.4% (4)                    | 1.2% (4)             | 1.9% (4)             | 0% (0)       | 0% (0)              | 0% (0)                | 0% (0)              | 0% (0)                 | 0.27        |

Odds ratios for age categories are compared to individuals <5 years-old, otherwise odds ratios are comparing individuals with pandemic influenza A (H1N1) to those with another respiratory virus; Congenital malformations, asthma, chronic obstructive pulmonary disease (COPD), chronic lung disease, previous serious or multiple lung infection/disease/intubation, cystic fibrosis, history of reactive airway disease or wheezing; Cirrhosis, end-stage liver disease, hepatitis, congenital abnormalities; Chronic kidney disease, end-stage renal disease, congenital disease, nephrotic syndrome, transplant recipient; Malignancy = leukemia, bladder, breast, head and neck, lung, lymphoma, medulloblastoma, prostate, multiple myeloma, neuroblastoma, ovarian, sarcoma; Seizure disorder, dementia, developmental delay, cerebral palsy, stroke, congenital, neuromuscular, trauma/surgery; Cardiac disease = arrhythmia, coronary artery disease, heart failure, congenital, valvular disease, cardiomyopathy, myocardial infarction; Human Immunodeficiency Virus; Systemic steroid use, transplant recipient, chemotherapy, human immunodeficiency virus (HIV).

doi:10.1371/journal.pone.0024734.t001
Table 2. Signs and symptoms of patients with pandemic 2009 influenza A (pH1N1) compared to other respiratory viruses.

| Symptom          | Total (n = 615) | Influenza A, H1N1 (n = 291) | All Others (n = 324) | Rhinovirus (n = 207) | RSV (n = 45) | Adenovirus (n = 27) | Parainfluenza (n = 37) | Coronavirus (n = 6) | Metapneumovirus (n = 2) | p-value | OR        |
|------------------|----------------|----------------------------|----------------------|----------------------|--------------|----------------------|------------------------|---------------------|-------------------------|---------|-----------|
| Fever            | 80.2% (493)    | 91.8% (267)                | 69.8% (226)          | 63.8% (132)          | 77.8% (35)   | 92.6% (25)           | 75.7% (28)             | 66.7% (4)          | 100.0% (2)              | <0.01   | 4.82 [2.98–7.80] |
| Mental Status    | 30.6% (188)    | 24.7% (72)                 | 35.8% (116)          | 30.9% (64)           | 48.9% (22)   | 40.7% (11)           | 45.9% (17)             | 33.3% (2)          | 0% (0)                   | <0.01   | 0.59 [0.42–0.84] |
| Weakness         | 17.2% (106)    | 26.8% (78)                 | 8.6% (28)            | 7.2% (15)            | 6.7% (3)     | 11.1% (3)            | 13.5% (5)              | 33.3% (2)          | 0% (0)                   | <0.01   | 3.87 [2.43–6.17] |
| Fatigue          | 15.0% (92)     | 19.6% (57)                 | 10.8% (35)           | 9.2% (19)            | 15.6% (7)    | 14.8% (4)            | 10.8% (4)              | 16.7% (1)          | 0% (0)                   | <0.01   | 2.01 [1.28–3.17] |
| Otitis Media     | 4.4% (27)      | 4.1% (12)                  | 4.6% (15)            | 4.8% (10)            | 2.2% (1)     | 7.4% (2)             | 0% (0)                 | 16.7% (1)          | 50.0% (1)                | 0.76    | 0.89 [0.41–1.93] |
| Conjunctivitis   | 2.0% (12)      | 1.0% (3)                   | 2.8% (9)             | 2.4% (5)             | 2.2% (1)     | 7.4% (2)             | 2.7% (1)               | 0% (0)              | 0% (0)                   | 0.12    | 0.37 [0.10–1.36] |
| Cough            | 88.5% (544)    | 91.1% (265)                | 86.1% (279)          | 85.0% (176)          | 86.7% (39)   | 85.2% (23)           | 94.6% (35)             | 66.7% (4)          | 100.0% (2)               | 0.06    | 1.64 [0.99–2.74] |
| Nasal Symptoms   | 56.7% (349)    | 56.7% (165)                | 56.8% (184)          | 52.2% (108)          | 71.1% (32)   | 70.4% (19)           | 54.1% (20)             | 66.7% (4)          | 50.0% (1)                | 0.98    | 1.00 [0.72–1.37] |
| Sore Throat      | 23.6% (145)    | 31.6% (92)                 | 16.4% (53)           | 17.4% (36)           | 4.4% (2)     | 11.1% (3)            | 24.3% (9)              | 33.3% (2)          | 50.0% (1)                | <0.01   | 2.36 [1.61–3.47] |
| Headache         | 19.7% (121)    | 29.6% (86)                 | 10.8% (35)           | 13.0% (27)           | 0% (0)       | 7.4% (2)             | 13.5% (5)              | 16.7% (1)          | 0% (0)                   | <0.01   | 3.46 [2.25–5.34] |
| Myalgia          | 20.7% (127)    | 31.6% (92)                 | 10.8% (35)           | 11.1% (23)           | 2.2% (1)     | 25.9% (7)            | 10.8% (4)              | 0% (0)              | 0% (0)                   | <0.01   | 3.82 [2.49–5.86] |
| Arthralgia       | 2.0% (12)      | 3.1% (9)                   | 0.9% (3)             | 1.0% (3)             | 0% (0)       | 0% (0)               | 2.7% (1)               | 0% (0)              | 0% (0)                   | 0.05    | 3.42 [0.92–12.74] |
| Chest Pain       | 16.4% (101)    | 23.4% (68)                 | 10.2% (33)           | 11.6% (24)           | 4.4% (2)     | 7.4% (2)             | 10.8% (4)              | 0% (0)              | 50.0% (1)                | <0.01   | 2.69 [1.71–4.22] |
| Dyspnea          | 58.7% (361)    | 52.9% (154)                | 63.9% (207)          | 64.7% (134)          | 73.3% (33)   | 59.3% (16)           | 59.5% (22)             | 33.3% (2)          | 0% (0)                   | <0.01   | 0.64 [0.46–0.88] |
| Wheezing         | 28.0% (172)    | 25.8% (75)                 | 29.9% (97)           | 32.9% (68)           | 31.1% (14)   | 29.6% (8)            | 16.2% (6)              | 16.7% (1)          | 0% (0)                   | 0.25    | 0.81 [0.57–1.16] |
| Nausea           | 19.0% (117)    | 31.3% (91)                 | 8.0% (26)            | 10.1% (21)           | 4.4% (2)     | 7.4% (2)             | 2.7% (1)               | 0% (0)              | 0% (0)                   | <0.01   | 5.22 [3.26–8.35] |
| Vomiting         | 34.5% (212)    | 39.2% (114)                | 30.2% (98)           | 26.1% (54)           | 40.0% (18)   | 40.7% (11)           | 37.8% (14)             | 16.7% (1)          | 0% (0)                   | 0.02    | 1.49 [1.06–2.07] |
| Abdominal Pain   | 10.7% (65)     | 14.4% (42)                 | 7.4% (24)            | 7.7% (16)            | 0% (0)       | 14.8% (4)            | 5.4% (2)               | 33.3% (2)          | 0% (0)                   | <0.01   | 2.11 [1.24–3.58] |
| Diarrhea         | 13.0% (80)     | 15.8% (46)                 | 10.5% (34)           | 7.2% (15)            | 11.1% (5)    | 22.2% (6)            | 21.6% (8)              | 0% (0)              | 0% (0)                   | 0.05    | 1.60 [1.00–2.58] |
| Anorexia         | 37.6% (231)    | 38.5% (112)                | 36.7% (119)          | 32.4% (67)           | 46.7% (21)   | 37.0% (10)           | 48.6% (18)             | 33.3% (2)          | 50.0% (1)                | 0.65    | 1.08 [0.78–1.50] |

OR = odds ratio.
doi:10.1371/journal.pone.0024734.t002
Table 3. Clinical characteristics of patients with pandemic influenza A (pH1N1) compared to other respiratory viruses.

|                                | Pandemic Influenza A (H1N1) | Other Respiratory Viruses |
|--------------------------------|------------------------------|---------------------------|
|                                | Mean [95% CI] | Min | Max | Mean [95% CI] | Min | Max | p-value |
| Duration of Symptoms (days)    | 3.3 [2.8–3.9] | 1.0 | 6.0 | 4.0 [3.4–4.5] | 1.0 | 5.6 | 0.10 |
| Max Temperature (°F)           | 100.9 [100.7–101.1] | 96.0 | 106.5 | 100.2 [99.9–100.4] | 92.4 | 110.3 | <0.01 |
| Max Heart Rate (min)           | 128.6 [125.1–132.0] | 65.0 | 220.0 | 140.8 [136.8–144.7] | 19.0 | 226 | <0.01 |
| Max Respiratory Rate (min)     | 31.5 [29.9–33.1] | 2.0 | 80.0 | 39.0 [37.0–41.1] | 14.0 | 168.0 | <0.01 |
| Lowest SBP* (mmHg)            | 105.7 [103.5–108.0] | 43.0 | 176.0 | 111.1 [108.5–113.6] | 11.0 | 202.0 | <0.01 |
| Corresponding DBP* (mmHg)      | 60.1 [58.6–61.7] | 12.0 | 98.0 | 64.9 [63.1–66.6] | 0.0 | 133.0 | <0.01 |
| Lowest Oxygen Saturation (%)   | 93.9 [93.2–94.7] | 30.0 | 100.0 | 95.2 [94.8–95.6] | 73.0 | 100.0 | <0.01 |
| Sodium (meq/L)                | 136.8 [136.4–137.2] | 127.0 | 146.0 | 136.7 [136.1–137.4] | 114.0 | 144.0 | 0.92 |
| Potassium (meq/L)             | 3.9 [3.8–4.0] | 2.6 | 6.1 | 4.1 [4.0–4.1] | 2.5 | 6.0 | <0.01 |
| Bicarbonate (meq/L)           | 24.3 [23.9–24.8] | 13.0 | 36.0 | 25.6 [24.0–27.2] | 12.0 | 107.0 | 0.13 |
| Chloride (meq/L)              | 102.6 [102.0–103.1] | 89.0 | 114.0 | 101.8 [100.2–103.4] | 21.0 | 116.0 | 0.36 |
| Creatinine (mg/dl)            | 0.94 [0.77–1.11] | 0.13 | 10.25 | 0.95 [0.58–1.32] | 0.09 | 28.0 | 0.95 |
| Blood urea nitrogen (mg/dl)   | 13.2 [11.4–14.9] | 2.0 | 118.0 | 12.6 [11.3–13.8] | 0.53 | 60.0 | 0.59 |
| Glucose (mg/dl)               | 135.6 [126.9–144.4] | 51.0 | 575.0 | 131.0 [123.1–138.9] | 0.66 | 377.0 | 0.44 |
| White blood count (×10^3/ml)  | 8.5 [8.1–9.0] | 0.7 | 21.5 | 13.6 [12.3–14.9] | 0.20 | 86.5 | <0.01 |
| Bands (%)                     | 2.8 [2.0–3.6] | 0.0 | 45.0 | 2.5 [1.8–3.2] | 0.0 | 36.0 | 0.61 |
| Hemoglobin (g/dl)             | 13.0 [12.8–13.3] | 7.2 | 18.3 | 12.2 [11.9–12.5] | 6.3 | 17.8 | <0.01 |
| Hematocrit (%)                | 38.0 [37.3–38.7] | 21.8 | 52.1 | 35.9 [35.1–36.8] | 19.1 | 51.7 | <0.01 |
| Platelets (×10^3/ml)          | 229.7 [218.6–240.8] | 13.0 | 539.0 | 288.7 [271.2–306.2] | 16.0 | 700.0 | <0.01 |
| Lactate (meq/L)               | 2.4 [1.3–3.5] | 0.4 | 23.6 | 2.0 [1.5–2.4] | 0.6 | 7.4 | 0.44 |
| AST (IU/L)                    | 52.0 [39.5–64.4] | 14.0 | 332.0 | 133.3 [−0.12–266.8] | 11.0 | 3273.0 | 0.23 |
| ALT (IU/L)                    | 36.6 [29.4–44.0] | 9.0 | 148.0 | 122.2 [107.0–233.7] | 8.0 | 2560.0 | 0.13 |
| Total Bilirubin (mg/dl)        | 0.8 [0.7–0.9] | 0.2 | 2.0 | 1.2 [0.7–1.6] | 0.2 | 11.2 | 0.08 |
| Direct Bilirubin (mg/dl)       | 0.2 [0.1–0.2] | 0.1 | 0.8 | 0.2 [0.1–0.3] | 0.1 | 1.4 | 0.21 |
| Alkaline Phosphate (IU/L)      | 95.2 [79.1–111.2] | 31.0 | 277.0 | 114.2 [91.0–137.4] | 48.0 | 477.0 | 0.18 |
| Protein (g/dl)                | 6.7 [6.5–6.9] | 5.0 | 9.0 | 6.5 [6.2–6.7] | 4.1 | 8.8 | 0.13 |
| Albumin (g/dl)                | 3.5 [3.3–3.6] | 2.2 | 4.9 | 3.2 [2.9–3.4] | 1.5 | 4.3 | 0.02 |
| PT (sec)                      | 32.9 [27.4–38.5] | 22.3 | 75.5 | 29.0 [23.5–34.4] | 11.8 | 41.9 | 0.31 |
| INR                           | 1.4 [1.1–1.7] | 0.9 | 3.6 | 1.5 [1.1–1.8] | 0.9 | 3.1 | 0.80 |
| Creatine Kinase (IU/L)         | 304.3 [166.4–442.1] | 15.0 | 2548.0 | 304.6 [379–571.2] | 14.0 | 2368.0 | 1.00 |
| MB Fraction (%)               | 1.7 [0.5–2.9] | 0.0 | 15.2 | 3.6 [−0.04–7.2] | 0.0 | 18.7 | 0.30 |
| Troponin I (ng/ml)            | 0.24 [0.10–0.37] | 0.08 | 2.8 | 0.82 [−0.15–1.78] | 0.03 | 9.0 | 0.23 |

*Systolic blood pressure; Diastolic blood pressure; CI = confidence intervals; PT = prothrombin time; PTT = partial thromboplastin time; INR = international normalized ratio; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
doi:10.1371/journal.pone.0024734.t003

microorganism. Forty-four percent (157/357) of patients with no evidence of acute disease or interstitial opacities indicative of viral infection on chest radiograph received antibacterial agents. Forty-six percent of the total cohort had blood sent for culture during their hospitalization, of which 2.5% grew a potential pathogenic microbe (i.e., coagulase-negative staphylococci and other potential skin contaminants were excluded). Twelve percent of the total cohort had a Legionella urine antigen test performed and all were negative.

There was no difference between patients infected with pH1N1 or another respiratory virus regarding admission to an intensive care unit, use of pressors or requirement for intubation (Table 5). However, individuals with pH1N1 were more likely to require bilevel positive airway pressure ventilation. Individuals with other respiratory viruses were more likely to receive inhaled bronchodilators or nebulizer therapy in the emergency department. Seven patients (1.1%) in the cohort died and these individuals were more likely to be infected with pH1N1 (2.1% vs. 0.3%, p<0.05).

In patients with cough, the presence of subjective fever/chills independently increased the likelihood of pH1N1 infection (Table 6). In patients with cough and gastrointestinal complaints, subjective fever/chills independently increased the likelihood of having pH1N1. Using fever alone did not raise the likelihood of having influenza infection versus another respiratory virus. Using age as a covariate, patients 19 to 59 years of age had the highest likelihood of presenting with pH1N1 compared to other age groups.

An age-adjusted analysis was performed to assess if any factors were found that significantly impacted the likelihood of patients...
### Table 4. Chest radiograph characteristics of patients with pandemic influenza A (pH1N1) compared to other respiratory viruses.

|                      | Total (n = 529) | Influenza A, H1N1 (n = 257) | All Others (n = 272) | Rhinovirus (n = 177) | RSV (n = 35) | Adenovirus (n = 26) | Parainfluenza (n = 27) | Coronavirus (n = 5) | Metapneumovirus (n = 2) | p-value | OR       |
|----------------------|-----------------|----------------------------|----------------------|----------------------|---------------|---------------------|------------------------|----------------------|------------------------|---------|----------|
|                      |                 |                            |                      |                      |               |                     |                        |                      |                        |         |          |
| NAD                  | 51.6% (273)     | 59.1% (152)                | 44.5% (121)          | 45.8% (81)           | 31.4% (11)    | 38.5% (10)          | 51.9% (14)             | 100.0% (5)           | 0% (0)                 | <0.01   | 1.81 [1.28–2.55] |
| IO                   | 15.9% (84)      | 10.9% (28)                 | 20.6% (56)           | 21.5% (38)           | 37.1% (13)    | 7.7% (2)            | 11.1% (3)               | 0% (0)               | 0% (0)                 | <0.01   | 0.47 [0.29–0.77]  |
| FASD                 | 18.7% (99)      | 18.7% (48)                 | 18.8% (51)           | 16.4% (29)           | 20.0% (7)     | 30.8% (8)           | 22.2% (6)              | 0% (0)               | 50.0% (1)              | 0.98    | 1.00 [0.64–1.54] |
| MFASD                | 9.6% (51)       | 7.4% (19)                  | 11.8% (32)           | 10.7% (19)           | 11.4% (4)     | 23.1% (6)           | 7.4% (2)               | 0% (0)               | 50.0% (1)              | 0.09    | 0.60 [0.33–1.09]  |
| Effusion             | 2.1% (11)       | 1.9% (5)                   | 2.2% (6)             | 2.3% (4)             | 2.9% (1)      | 0% (0)              | 3.7% (1)               | 0% (0)               | 0% (0)                 | 0.83    | 0.88 [0.27–2.92]  |

*a* No acute disease; 
*b* Interstitial Opacity consistent with viral disease; 
*focal air-space disease; 
multip focal air-space disease.

Other categories included edema (N = 16), collapse (N = 1), pneumomedistinum (N = 3). Patients could have multiple findings on chest radiograph (i.e. MFASD and effusion). OR = odds ratio.

doi:10.1371/journal.pone.0024734.t004

### Table 5. Treatment and outcomes of patients with pandemic influenza A (pH1N1) compared to other respiratory viruses.

|                      | Total (n = 615) | Influenza A, H1N1 (n = 291) | All Others (n = 324) | Rhinovirus (n = 207) | RSV (n = 45) | Adenovirus (n = 27) | Parainfluenza (n = 37) | Coronavirus (n = 6) | Metapneumovirus (n = 2) | p-value | OR       |
|----------------------|-----------------|----------------------------|----------------------|----------------------|---------------|---------------------|------------------------|----------------------|------------------------|---------|----------|
|                      |                 |                            |                      |                      |               |                     |                        |                      |                        |         |          |
| Oseltamivir          | 62.6% (385)     | 79.0% (230)                | 47.8% (155)          | 44.4% (92)           | 53.3% (24)    | 55.6% (15)          | 56.8% (21)             | 33.3% (2)            | 50.0% (1)              | <0.01   | 4.11 [2.88–5.87] |
| Other antiviral      | 0.8% (5)        | 1.4% (4)                   | 0.3% (1)             | 0% (0)               | 2.2% (1)      | 0% (0)              | 0% (0)                 | 0% (0)               | 0% (0)                 | 0.14    | 4.50 [0.50–40.51] |
| Antibacterial agents | 54.6% (336)     | 55.0% (160)                | 54.3% (176)          | 52.7% (109)          | 46.7% (21)    | 77.8% (21)          | 54.1% (20)             | 50.0% (3)            | 100.0% (2)             | 0.87    | 1.03 [0.75–1.41]  |
| Steroids             | 41.0% (252)     | 34.4% (100)                | 46.9% (152)          | 52.7% (109)          | 46.7% (21)    | 37.0% (10)          | 27.0% (10)             | 16.7% (1)            | 50.0% (1)              | <0.01   | 0.59 [0.43–0.82]  |
| ICU Admission        | 16.9% (104)     | 16.2% (47)                 | 17.6% (57)           | 18.4% (38)           | 22.2% (10)    | 14.8% (4)           | 10.8% (4)              | 16.7% (1)            | 0% (0)                 | 0.56    | –        |
| Intubation           | 3.7% (23)       | 3.4% (10)                  | 4.0% (13)            | 3.9% (8)             | 4.4% (2)      | 7.4% (2)            | 0% (0)                 | 0% (0)               | 0% (0)                 | 0.07    | 0.85 [0.37–1.97]  |
| Bi-pap               | 3.6% (22)       | 5.2% (15)                  | 2.2% (7)             | 1.4% (3)             | 2.2% (1)      | 3.7% (1)            | 0% (0)                 | 16.7% (1)            | 50.0% (1)              | 0.046   | 2.46 [0.99–6.12]  |
| Nebulizers or Inhalers| 52.5% (323)    | 46.7% (136)                | 57.7% (187)          | 59.9% (124)          | 75.6% (34)    | 44.4% (12)          | 40.5% (15)             | 16.7% (1)            | 50.0% (1)              | 0.02    | –        |
| Pressors             | 1.8% (11)       | 2.7% (8)                   | 0.9% (3)             | 1.0% (2)             | 0% (0)       | 3.7% (1)            | 0% (0)                 | 0% (0)               | 0% (0)                 | 0.09    | 3.02 [0.79–11.50] |
| Death                | 1.1% (7)        | 2.1% (6)                   | 0.3% (1)             | 0.5% (1)             | 0% (0)       | 0% (0)              | 0% (0)                 | 0% (0)               | 0% (0)                 | 0.04    | 6.80 [0.81–56.77] |

ICU = intensive care unit; OR = odds ratio; Bi-pap = bilevel positive airway pressure.

doi:10.1371/journal.pone.0024734.t005
Table 6. Likelihood of patients with clinical characteristics having pandemic 2009 influenza A (pH1N1) using multiple logistic regressions.

| Likelihood of having pandemic 2009 influenza A (H1N1)                                      | OR   | [95% CI] |
|------------------------------------------------------------------------------------------|------|---------|
| Subjective fever/chills in patients with cough and gastrointestinal complaints           | 9.96 | [4.04–24.59] |
| Subjective fever/chills in patients with cough and no gastrointestinal complaints        | 4.02 | [2.03–7.99] |
| Subjective fever/chills in patients without cough or gastrointestinal complaints         | 0.70 | [0.20–2.47] |
| Cough in patients with subjective fevers/chills                                          | 1.79 | [0.97–3.31] |
| Cough in patients without subjective fevers/chills                                       | 0.31 | [0.09–1.01] |
| Gastrointestinal complaints in patients with subjective fevers/chills                    | 2.29 | [1.57–3.34] |
| Gastrointestinal complaints in patients without subjective fevers/chills                 | 0.92 | [0.34–2.54] |
| ≤60 years-old versus 19–59 years-old                                                    | 0.22 | [0.11–0.44] |
| ≥60 years-old versus 5–18 years-old                                                     | 0.27 | [0.13–0.56] |
| ≥60 years-old versus <5 years-old                                                       | 1.30 | [0.65–2.58] |
| 19–59 years-old versus 5–18 years-old                                                    | 1.26 | [0.78–2.04] |
| 19–59 years-old versus <5 years-old                                                     | 5.98 | [3.86–9.24] |
| 5–18 years-old versus <5 years-old                                                      | 4.75 | [3.02–7.47] |

OR = odds ratio; CI = confidence intervals.
doi:10.1371/journal.pone.0024734.t006

Discussion

In patients with viral respiratory infections, diagnosis of influenza is important to provide timely and efficient treatment with neuraminidase inhibitors. Rapid antigen tests were insensitive in the diagnosis of influenza during the 2009–2010 pandemic season [29,6,30]. Furthermore, these tests could not distinguish between different influenza A subtypes [31]. Seasonal influenza A (H1N1) was resistant to oseltamivir, whereas pH1N1 was not, making this a critical distinction [32]. While state public health labs had a CDC-based PCR assay for distinguishing influenza subtypes, an FDA-cleared product for clinical laboratories was delayed [33]. Therefore, many institutions, including our own, implemented a molecular-based test to diagnose influenza A [34]. The Luminex xTAG RVP was highly sensitive and able to distinguish 18 viruses causing respiratory infections, including different influenza subtypes.

With the introduction and effectiveness of molecular testing, one goal is more efficient use of antimicrobials and the reduction of unnecessary antibiotic use. Despite the relatively rapid turnaround time of the PCR-based tests, greater than half of the patients in our cohort with documented viral infections received antibacterial agents, presumably for empiric coverage of bacterial pneumonia. Furthermore, almost half of patients without influenza received oseltamivir. As such, implementation of rapid diagnostic testing for respiratory pathogens alone may not limit antibiotic use without other interventions. These data suggest overuse of antibacterial and antiviral agents and an opportunity for a robust antimicrobial stewardship program.

Clinical characteristics of hospitalized patients with pH1N1 were variable. Fever and cough, two criteria for ILI, often occur in influenza A patients [3,14,12,15–18,20,21,24]. Although more patients with pH1N1 presented with fever and sore throat compared to those with other viruses in our population, the difference was not enough to make a firm clinical diagnosis of influenza. Furthermore, there was no significant difference in cough alone between patients infected with pH1N1 and other respiratory viruses. However, fever, cough, and gastrointestinal symptoms increased the likelihood of pH1N1 almost 10-fold in the pediatric population and may be useful as a preliminary guide to prompt clinicians to treat influenza infection. Chest radiographs may be useful in diagnosing superimposed bacterial infection. While airspace disease was observed more often in patients with non-influenza viruses, there were no chest radiographic findings that distinguish influenza infection. Over half of patients with pH1N1 had non-specific findings on chest radiograph as previously reported [24].

Our study supports previous findings that pH1N1 tends to infect younger adults, sparing the elderly and young children [3,14,15,17,19,18,20,21]. We found lower rates of influenza from nursing home patients reflecting this age distribution. Of those that died or were hospitalized, many had co-morbidities as previously reported [15,17,19,21,35,36]. In contrast to other studies [15,37,38,21,19], we did not find a high infection or mortality rate during pregnancy but our study was underpowered due to the low number of pregnant women in our cohort.

The mortality rate of 2.1% for hospitalized patients with pH1N1 infection in our cohort was lower than other reports [14,15]. Despite this, it was significantly higher than the mortality associated with other respiratory viral infections and highlights the importance of accurate diagnosis and early treatment of influenza infection.
Aside from the retrospective nature of our study, a potential limitation was the small number of pregnant women likely due to the presence of a neighboring obstetrics and gynecologic hospital. A second limitation was the time period for which patients presenting with ILI were evaluated (6 weeks at the peak of the pandemic) whereas a typical respiratory season would be for several months and include a greater variety of viruses, especially in the pediatric population. In fact, our data (not shown) does indicate that after the pandemic wave at our institution, a typical peak for RSV, metapneumovirus and paramyxovirus viruses followed the presence of pH1N1, much like the rest of the country. A third limitation was that pH1N1 confirmatory testing was not performed for all nonsubtypeable influenza A viruses. However, recent literature suggests that 100% of non-subtypeable influenza A H1 identified by the xTAG RVP was pH1N1 [39] and that misinterpretation is uncommon [40]. In addition, our initial investigation of a large number of strains early in the pandemic with the CDC PCR assay confirmed these findings. Many prior studies only assessed the clinical characteristics of patients with influenza or compared to individuals who’s respiratory tests were negative for influenza, but they did not further delineate those without influenza or positive for another virus [14,16,18,20,21,25,26]. We set out to compare pandemic 2009 influenza A (H1N1) to other respiratory viruses in patients with ILL. To our knowledge, these results provide the first comparison of clinical characteristics between pH1N1 and other common respiratory viruses.

While a specific clinical presentation could not confirm pH1N1 in patients with cough and gastrointestinal complaints, the presence of subjective fever and/or chills increased the likelihood of pH1N1 infection versus another virus. Respiratory infection with pH1N1 infection more often resulted in death compared to other respiratory viruses and should be treated aggressively with supportive measures and antiviral medications. Despite the use of RVP testing, many influenza-infected patients received antibacterial agents and many patients without influenza received antivirals. Use of a highly accurate RVP in conjunction with a robust antimicrobial stewardship program will be necessary to assure prudent antibacterial and antiviral agent use in the future.

Materials and Methods

Ethics

The study was approved by the Rhode Island Hospital institutional review board. A waiver of informed consent was obtained before onset of the study.

Study Design

A retrospective review was performed of all individuals presenting to our hospital system between October 16, 2009 and December 1, 2009 who had a positive respiratory viral panel (RVP, Luminex xTAG®; Luminex Corporation, Austin, TX). All predictors were tested for an interaction with different age categories (<5 years, 5–18 years, 19 years and older) with regards to predicting pH1N1 in logistic regressions. Models included main effects for the predictor, age, and the interaction of the two. When a statistically significant interaction was detected, the simple effects of the predictors were described in terms of their effects within age categories. Those which did not significantly interact with age were described in terms of their main effect.

Author Contributions

Conceived and designed the experiments: PAC LAM KCC. Performed the experiments: SBA KCC. Analyzed the data: PAC LAM KCC. Contributed reagents/materials/analysis tools: KC JTM. Wrote the paper: PAC LAM KCC.

References

1. Greenberg SB (1991) Viral pneumonia. Infect Dis Clin North Am 5: 603–621.
2. Thompson WW, Moore MR, Weinraub E, Cheng P, Jin X, et al. (2009) Estimating influenza-associated deaths in the United States. Am J Public Health 99 Suppl 2: S225–230. doi:10.2105/AMJP.2008.151944.
3. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605–2615. doi:10.1056/NEJMoa0903810.
4. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, et al. (2009) Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N Engl J Med 360: 2616–2625. doi:10.1056/NEJMoa0903810.
5. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, et al. (2009) Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 48: 1003–1032. doi:10.1086/598513.
6. Gordon A, Videa E, Saborio S, Lopez R, Kuan G, et al. (2010) Diagnostic accuracy of a rapid influenza test for pandemic influenza A H1N1. PLoS ONE 5: e10364. doi:10.1371/journal.pone.0010364.
7. Landry ML (2011) Diagnostic tests for influenza infection. Curr Opin Pediatr 23: 91–97. doi:10.1097/MOP.0b013e32834f6051.
8. Cunha BA, Syed U, Strollo S, McKail N, Laguerre M (2010) Rapid clinical diagnosis of swine influenza (H1N1) using the Swine influenza diagnostic trial. Heart Lung 39: 461. doi:10.1016/j.hrtlng.2010.01.003.
9. Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RTR, et al. (2008) Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 63: 42–48. doi:10.1136/thx.2006.075077.
10. Babcock HM, Merz LR, Dubberke ER, Fraser VJ (2008) Case-control study of clinical features of influenza in hospitalized patients. Infect Control Hosp Epidemiol 29: 921–926. doi:10.1089/ice.2008.0451.

11. Boivin G, Hardy I, Feller G, Mazelde J (2009) Predicting influenza infections during periods of limited use of a clinical case definition. Clin Infect Dis 31: 1166–1169. doi:10.1086/573187.

12. Bryant PA, Teheruge M, Papadakis K, Clarke C, Barnett P, et al. (2010) Clinical and microbiologic features associated with novel swine-origin influenza A pandemic 2009 (H1N1) virus in children: a prospective cohort study. Pediatr Infect Dis J 29: 694–698. doi:10.1097/INF.0b013e3181de4f8c.

13. Centers for Disease Control and Prevention (2010) Outbreak of 2009 pandemic influenza A (H1N1) at a school - Hawaii, May 2009. MMWR Morb Mortal Wkly Rep 58: 1440–1444.

14. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, et al. (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 361: 680–689. doi:10.1056/NEJMoa0906252.

15. Louie JK, Acosta M, Winter K, Jean C, Gavali S, et al. (2009) Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 302: 1896–1892. doi:10.1001/jama.2009.1503.

16. Lesar J, Reich NG, Cummings DAT, Nair HP, Jordan HT, et al. (2009) Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med 361: 2628–2636. doi:10.1056/NEJMoa0906889.

17. Lee EH, Wu C, Lee EU, Stoute A, Hanson H, et al. (2010) Fatalities associated with the 2009 H1N1 influenza A virus in New York City. Clin Infect Dis 40: 1498–1504. doi:10.1086/652466.

18. Crum-Cianflone NF, Blair PJ, Faix D, Arnold J, Echols S, et al. (2009) Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis 49: 1801–1810. doi:10.1086/646508.

19. Bautista E, Chotipayawoonsri T, Gao Z, Harper SA, Shaw M, et al. (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362: 1708–1719. doi:10.1056/NEJMoa1000449.

20. Cao B, Li X, Mao Y, Wang J, Lu H, et al. (2009) Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 361: 2507–2517. doi:10.1056/NEJMoa0906612.

21. Jain S, Kamimoto L, Cummings DAT, Benoit SR, et al. (2009) Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 361: 1935–1944. doi:10.1056/NEJMoa0906695.

22. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, et al. (2009) Critically ill patients with 2009 influenza A(H1N1) infection in Mexico. JAMA 302: 1872–1879. doi:10.1001/jama.2009.1536.

23. Kumar A, Zarzanychanski R, Pinto R, Cook DJ, Marshall J, et al. (2009) Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302: 1872–1879. doi:10.1001/jama.2009.1496.

24. Cunha BA (2010) Swine Influenza (H1N1) pneumonia: clinical considerations. Infect Dis Clin North Am 24: 203–228. doi:10.1016/j.cinc.2009.10.001.

25. Belongia EA, Irving SA, Waring SC, Coleman LA, Meece JK, et al. (2010) Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008–2009 (H1N1), and 2007–2008 (H1N2) infections. JAMA 304: 1091–1098. doi:10.1001/jama.2010.1277.

26. Carrion D, Giel C, Dowse GK, Mak DB, Goggan L, et al. (2010) Comparison of pandemic (H1N1) 2009 and seasonal influenza, Western Australia, 2009. Emerging Infect Dis 16: 1388–1395.

27. Wighton RS, Darr CA, Corbertt KK, Nickol DR, Gonzales R (2008) How do community practitioners decide whether to prescribe antibiotics for acute respiratory tract infection? J Gen Intern Med 23: 1615–1620. doi:10.1007/s11606-008-0707-9.

28. Gootz TD (2010) The global problem of antibiotic resistance. Crit Rev Immunol 30: 79–93.

29. Leonard GP, Mirache I, Piall A, Freedman L (2010) Public hospital-based laboratory experience during an outbreak of pandemic influenza A (H1N1) virus infections. J Clin Microbiol 48: 1189–1194. doi:10.1128/JCM.01657-09.

30. Ganzensmoller T, Kluba J, H"{u}lrich B, Puppe W, Verhagen W, et al. (2010) Comparison of the performance of direct fluorescent antibody staining, a point-of-care rapid antigen test and virus isolation with that of RT-PCR for the detection of novel 2009 influenza A (H1N1) virus in respiratory specimens. J Med Microbiol 59: 713–717. doi:10.1099/jmm.0.017244-0.

31. Boggild AK, McGeer AJ (2010) Laboratory diagnosis of 2009 H1N1 influenza A virus. Crit Care Med 38: 38–42. doi:10.1097/CCM.0b013e3181c7b8b2.

32. Update: drug susceptibility of swine-origin influenza (H1N1) viruses, April 2009 (2009) MMWR Morb Mortal Wkly Rep 58: 435–433.

33. Medina RA, Rojas M, Tuin A, Hull S, Ferres M, et al. (2011) Development and characterization of a highly specific and sensitive SYBR green reverse transcriptase PCR assay for detection of the 2009 pandemic H1N1 influenza virus on the basis of sequence signatures. J Clin Microbiol 49: 335–344. doi:10.1128/JCM.01442-10.

34. Fox JD (2007) Nucleic acid amplification tests for detection of respiratory viruses. J Clin Virol 40 Suppl 1: S1–S12. doi:10.1016/S1386-6532(07)70005-7.

35. Donaldson LJ, Rutter PD, Elliott BM, Myton OT, et al. (2009) Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 339: b2521.

36. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Ochoa AJ, Grajales-Munoz C, Robles-Perez E, et al. (2009) Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374: 1072–1079. doi:10.1016/S0140-6736(09)61638-X.

37. Webb SAR, Pettila V, Seppelt I, Bellomo R, Bailey M, et al. (2009) Critical care and epidemiologic characteristics of an outbreak of pandemic (H1N1) 2009 and seasonal influenza, Western Australia, 2009. Emerg Infect Dis 16: 27–35. doi:10.3201/eid1601.090444.

38. Ginocchio CC, Zhang F, Manji R, Bornfreund M, et al. (2009) Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol 45(3): 191–5.

39. Welch DF, Ginocchio CC (2010) Role of rapid immunochromatographic antigen testing in diagnosis of influenza A virus 2009 H1N1 infection. J Clin Microbiol 48: 22–25. doi:10.1128/JCM.02268-09.